<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Three children treated with bone marrow transplantation for <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo>, Diamond-Blackfan <z:hpo ids='HP_0001903'>anemia</z:hpo>, and congenital <z:hpo ids='HP_0004859'>amegakaryocytic thrombocytopenia</z:hpo> developed secondary <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> in the left tibia at the age of 13, 13, and 9 years, respectively, at 51, 117, and 106 months after transplantation, respectively </plain></SENT>
<SENT sid="1" pm="."><plain>Through treatment with chemotherapy and surgery, <z:hpo ids='HP_0000001'>all</z:hpo> 3 patients are alive without disease </plain></SENT>
<SENT sid="2" pm="."><plain>We surveyed the literature and reviewed 10 cases of <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> after hematopoietic stem cell transplantation (SCT), including our 3 cases </plain></SENT>
<SENT sid="3" pm="."><plain>Eight of the patients had received myeloablative total body irradiation before SCT </plain></SENT>
<SENT sid="4" pm="."><plain>The mean interval from SCT to the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> was 6 years and 4 months, and the mean age at the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> was 14 years and 5 months </plain></SENT>
<SENT sid="5" pm="."><plain>The primary site of the post-SCT <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo> was the tibia in 6 of 10 cases, in contrast to de novo <z:hpo ids='HP_0002669'>osteosarcoma</z:hpo>, in which the most common site is the femur </plain></SENT>
<SENT sid="6" pm="."><plain>At least 7 of the 10 patients are alive without disease </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0002669'>Osteosarcoma</z:hpo> should be one of the items for surveillance in the follow-up of patients who undergo SCT </plain></SENT>
</text></document>